Timber Pharmaceuticals, Inc. (TMBR)
| Market Cap | 6.53M |
| Revenue (ttm) | 928,975 |
| Net Income (ttm) | -11.93M |
| Shares Out | 63.75M |
| EPS (ttm) | -0.25 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 24,147,350 |
| Open | 0.106 |
| Previous Close | 0.103 |
| Day's Range | 0.101 - 0.109 |
| 52-Week Range | 0.090 - 1.120 |
| Beta | -0.17 |
| Analysts | Buy |
| Price Target | 1.53 (+1,394.1%) |
| Earnings Date | Aug 8, 2022 |
About TMBR
Timber Pharmaceuticals LLC, a clinical-stage biopharmaceutical company, engages in the development and commercialization of treatments for orphan dermatologic diseases. The company's lead product candidates include TMB-001, a patented topical formulation of isotretinoin that has completed Phase 2b clinical trial for the treatment of moderate to severe subtypes of CI, a group of rare genetic keratinization disorders; and TMB-002, a proprietary topical formulation of rapamycin, which is in Phase 2b clinical trial for the treatment of facial angio... [Read more...]
Financial Performance
In 2021, TMBR's revenue was $886,532, an increase of 95.35% compared to the previous year's $453,810. Losses were -$10.64 million, -29.62% less than in 2020.
Financial StatementsAnalyst Forecast
According to 7 analysts, the average rating for TMBR stock is "Buy." The 12-month stock price forecast is 1.53, which is an increase of 1,394.14% from the latest price.
News
Timber Pharmaceuticals Announces Closing of $8.0 Million Public Offering
Basking Ridge, NJ, Aug. 08, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- Timber Pharmaceuticals, Inc. (“Timber” or the “Company”) (NYSE American: TMBR), a biopharmaceutical company focused on the deve...
Timber Pharmaceuticals Announces Pricing of $8.0 Million Public Offering
Basking Ridge, NJ, Aug. 04, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- Timber Pharmaceuticals, Inc. (“Timber” or the “Company”) (NYSE American: TMBR), a biopharmaceutical company focused on the devel...
Timber Pharmaceuticals Announces First Patients Enrolled in Phase 3 ASCEND Clinical Trial Evaluating TMB-001 in Conge...
Pivotal Trial Expected to Enroll More Than 140 Patients With Moderate to Severe Congenital Ichthyosis at Leading Research Centers in the U.S., Canada, Italy, France, and Germany
Timber Pharmaceuticals Receives FDA Breakthrough Therapy Designation for TMB-001 for the Treatment of Congenital Icht...
- Company preparing to dose first patients in pivotal Phase 3 ASCEND clinical trial -
Timber Pharmaceuticals Provides Business Update and Announces First Quarter 2022 Financial Results
Lead Asset TMB-001 Receives Fast Track Designation in Advance of Phase 3 Study Initiation by June 30th, 2022
Best Penny Stocks to Buy Under $1? 3 to Watch as April Ends
Are these under $1 penny stocks on your watchlist? The post Best Penny Stocks to Buy Under $1?
Timber Pharmaceuticals Announces Fast Track Designation Granted by FDA for TMB-001 in Severe Subtypes of Congenital I...
Company expects to launch pivotal Phase 3 ASCEND clinical trial to evaluate TMB-001 within the next 60 days
Timber Pharmaceuticals Provides Business Update and Announces Fourth Quarter and Year End 2021 Financial Results
Company Plans to Initiate Phase 3 Study for TMB-001 in Q2 2022
Timber Pharmaceuticals Announces Late-Breaking Presentation at the American Academy of Dermatology 2022 Annual Meeting
Sub-analysis of the Phase 2b CONTROL study in congenital ichthyosis demonstrates treatment success with TMB-001 regardless of subtype
Timber Pharmaceuticals: Invitation to the Q1 Virtual Investor Summit
Basking Ridge, New Jersey--(Newsfile Corp. - February 28, 2022) - Timber Pharmaceuticals (NYSE American: TMBR) today announced that John Koconis, Chairman and CEO will be attending the Q1 Virtual Invest...
Timber Pharmaceuticals Announces Positive End-of-Phase 2 Meeting with FDA for TMB-001 in Moderate to Severe Congenita...
- Full data from Phase 2b CONTROL study presented at 2022 Winter Clinical Dermatology Conference -
Timber Pharmaceuticals to Present at H.C. Wainwright BioConnect Conference
Virtual Conference on January 10-13, 2022
Timber Pharmaceuticals to Host Conference Call Discussing Positive Topline Results from Phase 2b CONTROL Study of Con...
Call to be held on Monday, November 22nd at 10:00am ET
Timber Pharmaceuticals Provides Business Update and Announces Third Quarter 2021 Financial Results
Positive Top Line Phase 2b Study Data for Lead Asset TMB-001 and Capital Rais e of $17.25 Million Announced Subsequent to Quarter End
Timber Pharmaceuticals Announces Closing of Exercise of Underwriter's Option to Purchase Additional Common Stock
Underwritten Public Offering Resulted in Total Gross Proceeds of $17.25 Million
Timber Pharmaceuticals Announces Closing of $15 Million Public Offering
Basking Ridge, NJ, Nov. 05, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- Timber Pharmaceuticals, Inc. (“Timber” or the “Company”) (NYSE American: TMBR), a biopharmaceutical company focused on the devel...
Timber Pharmaceuticals Announces Pricing of $15 Million Public Offering
Basking Ridge, NJ, Nov. 03, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire --Timber Pharmaceuticals, Inc. (“Timber” or the “Company”) (NYSE American: TMBR), a biopharmaceutical company focused on the develo...
Timber Pharmaceuticals Announces Proposed Public Offering
Basking Ridge, NJ, Nov. 02, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- Timber Pharmaceuticals, Inc. (“Timber” or the “Company”) (NYSE American: TMBR), a biopharmaceutical company focused on the develo...
Timber Pharmaceuticals Reports Positive Top-line Results from Phase 2b CONTROL Study Evaluating TMB-001 in Moderate t...
Basking Ridge, NJ, Oct. 07, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- Timber Pharmaceuticals, Inc. ("Timber" or the “Company”) (NYSE American: TMBR), a biopharmaceutical company focused on the devel...
Timber Pharmaceuticals to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
BASKING RIDGE, NJ, Sept. 10, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire – Timber Pharmaceuticals, Inc. ("Timber" or the “Company”) (NYSE American: TMBR), a biopharmaceutical company focused on the develo...
Timber Pharmaceuticals Announces Last Patient Last Visit in Phase 2b CONTROL Study Evaluating TMB-001 in Moderate to ...
- Topline results expected to be announced in the fourth quarter of 2021 -
7 Hottest Penny Stocks to Pick Up Now
Penny stocks from companies that have reasonable business fundamentals. Stocks that can possibly provide multi-fold returns.
Timber Pharmaceuticals Provides Business Update and Announces Second Quarter 2021 Financial Results
BASKING RIDGE, NJ, Aug. 10, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- Timber Pharmaceuticals, Inc. ("Timber" or the “Company”) (NYSE American: TMBR), a biopharmaceutical company focused on the develo...
7 Reddit Penny Stocks to Watch for Big Upside Ahead
If we've learned anything from the Reddit in January, it's not to underestimate them. These 7 Reddit penny stocks have good upsides.
Timber Pharmaceuticals Announces Adjournment of Annual Meeting
Basking Ridge, NJ, June 03, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- Timber Pharmaceuticals, Inc. ("Timber" or the “Company”) (NYSE American: TMBR), a biopharmaceutical company focused on the develo...